Apr 01,2024

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack, a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership (“TTP”), announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor, suggesting sensor longevity beyond three years, a year longer than the Company previously announced. Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation. The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 12,2024

SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS

Ascensia Diabetes Care and Senseonics Holdings have extended the Eversense Payment Assistance and Simple Savings (PASS) Program in the U.S., aimed at making the Eversense E3 CGM System more accessible. Eligible individuals will pay only $99 for an unlimited number of 6-month Eversense E3 systems, equivalent to an average monthly cost of $16.50 and a total out-of-pocket cost of less than $200 for each entire year of continuous glucose monitoring with Eversense E3, excluding the costs of insertion and removal. The program, initially launched in April 2022, has expanded its coverage to include a whole year of continuous glucose monitoring and more commercially insured people with diabetes. Eligibility requires a commercial insurance plan and meeting medical coverage criteria for CGM. Exclusions apply to government insurance and certain commercial insurance plans.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 07,2024 TOP STORY

Roche unveils new CGM tech with predictive AI, outlines diabetes strategy

Roche gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI. The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy.  Julien Boisdron, Roche Diabetes Care’s chief medical officer, called it “a solution more than a CGM” during the event. Roche aims to bring the real-time CGM to both the type 1 and type 2 diabetes populations, including for those on insulin therapy. Users can share their data with healthcare professionals and it has a differentiating predictive algorithm included. Based on the CGM data of the person with diabetes, the system’s app shows where glucose levels might go in the next two hours at any given point in time. With the device still investigational, there is still plenty going into the development efforts at Roche. That includes the potential for connecting the CGM to insulin pumps, like other CGM makers have done.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 06,2024 TOP STORY

REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRE® SYSTEMS AND GLP-1 MEDICINES WORK BETTER TOGETHER FOR PEOPLE WITH TYPE 2 DIABETES

Abbott announced new data showing that individuals with Type 2 diabetes using GLP-1 medicines alongside FreeStyle Libre technology experienced greater improvement in their HbA1c levels compared to those using GLP-1 medicines alone. GLP-1 medicines stimulate insulin release and aid weight loss in Type 2 diabetes management. The studies presented at ATTD revealed significant HbA1c improvements (-1.5% to -2.4%) after adding FreeStyle Libre technology to GLP-1 therapy, regardless of GLP-1 duration or insulin therapy. This combination enhances glycemic control and supports positive behavior changes by providing real-time glucose data.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2024

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Insulet Corporation presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System. The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes in Florence, Italy. Insulet presented data for 194 adults who had used traditional (non-AID) insulin pump therapy (including 87% using the Omnipod or Omnipod DASH® Insulin Management System) for three months or longer and had a HbA1c between 7 and 11% (mean 8.5%). The participants had type 1 diabetes for at least one year and were enrolled at 14 institutions across the United States (61%) and France (39%). The participants were randomized into two groups and studied over the course of 13 weeks. The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6. According to the results presented, the participants using Omnipod 5 showed a significantly greater TIR by 17.5% (43.8% in Control group versus 61.2% in Intervention group), or an additional 4.2 hours per day, and a greater reduction in HbA1c by 0.58% (1.24% with Omnipod 5 vs. 0.68% in the Control group). The final HbA1c was 7.25% in the Omnipod 5 group versus 7.84% in the Control group.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2024 TOP STORY

Dexcom over-the-counter Stelo Glucose Biosensor wins FDA clearance

Dexcom has received FDA clearance for its over-the-counter continuous glucose monitoring (CGM) solution called Stelo, which offers round-the-clock glucose readings directly to smartphones. The wearable biosensor has a two-week battery life and detects normal as well as low or high glucose levels. It's tailored for adults managing diabetes with oral medications or needing insight into lifestyle impacts on blood sugar levels. While not indicated for problematic hypoglycemia, it aims to empower users with actionable insights. Stelo is set for online release in summer 2024.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 05,2024

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Dexcom has unveiled new clinical evidence supporting CGM use for automated insulin delivery systems and demonstrated benefits for managing Type 2 diabetes at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence. They highlighted the positive outcomes of using their CGM in AID systems, including reduced severe hypoglycemia and diabetic ketoacidosis rates. The company also announced the launch of their G7 sensor in additional markets and the introduction of Dexcom ONE+. Dexcom also announced the phased launch of direct connectivity to Apple Watch for G7 iOS users, beginning with a phased launch available to all G7 iOS users in the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone. Additionally, the company presented evidence linking CGM use to reduced mortality in people with Type 1 and Type 2 diabetes. They showcased data indicating improved HbA1c and glucose range for Type 2 diabetes patients using their CGM sensors, emphasizing the device's role in enhancing metabolic health.

PRODUCT

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 27,2024

These diabetes devices are set to launch in 2024

In 2024, the diabetes technology landscape is poised for significant advancements with several major product launches. Medtronic introduces its MiniMed 780G automated insulin delivery system, featuring the Simplera Sync sensor, set for a phased commercial launch in Europe in the summer. Dexcom anticipates the launch of its Stelo glucose monitor designed for non-insulin users in the U.S. during the summer, offering a 15-day wear with a unique software experience. Insulet plans to release its Omnipod GO long-acting insulin delivery system for type 2 diabetes in 2024. Tandem Diabetes Care has already launched its Mobi insulin patch pump, a durable automated insulin delivery system. Dexcom has introduced Dexcom ONE+ in Europe, utilizing the G7 sensor and providing real-time continuous glucose monitoring. Additionally, notable integrations include Insulet Omnipod 5 with Dexcom's G7 and Abbott's FreeStyle Libre 2 Plus, and Tandem Diabetes Care's t:slim X2 with Dexcom's G7 and Abbott's FreeStyle Libre 2 Plus. Companies like Embecta, Modular Medical, and PharmaSens have submitted innovative patch pump systems to the FDA for potential launch pending approval, showcasing the dynamic landscape of diabetes technology in 2024.

PRODUCT

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Nova Scotia announces expanded coverage for insulin pumps and advanced glucose monitoring

The Government of Nova Scotia announced a historic investment to provide better access to diabetes devices such as insulin pumps and glucose monitors for Nova Scotians with diabetes. The province will be investing $5.9 million to fund sensor-based glucose monitoring supplies, and $1.3 million to expand the Nova Scotia Insulin Pump Program by removing the current age cap. Glucose monitoring supplies will be obtained through a new income-based program and through existing pharmacare programs. While Nova Scotians living with either type 1 diabetes (T1D) or type 2 diabetes can access this new program, eligibility requirements will include the need for multiple daily injections of insulin or insulin pumps to manage their diabetes.

#reimbursement

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 27,2024

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack announced the selection of Cirtec Medical Corp, the leading medical device solutions provider of implantable therapies, as manufacturer for the implantable Continuous Blood Glucose Monitor (CBGM). The two companies have signed a development agreement for clinical and commercial manufacturing. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with a once-only calibration event. The company continues to reach significant milestones, such as the recently announced completion of its first preclinical study in animals.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM